SEMAGLUTIDE (RYBELSUS) AND LOSING WEIGHT

Hassan Mohsen Alalasi; Riyadh Mohammed Alahmadi; Abdulllah Ali Al-Zahrani; Omar Amr Ghayouth

doi:10.53555/jptcp.v29i02.4506

Hassan Mohsen Alalasi
Riyadh Mohammed Alahmadi
Abdulllah Ali Al-Zahrani
Omar Amr Ghayouth

Keywords

Semaglutide, obesity, weight loss, RYBELSUS, clinical trials, mechanism of action

Abstract

Semaglutide (RYBELSUS) is a medication that has been recently approved by the FDA for use in the management of obesity and weight loss. This essay explores the effectiveness of semaglutide in promoting weight loss and the associated benefits. The introduction provides an overview of the obesity epidemic and the need for novel treatment options. The results section presents scientific evidence regarding the efficacy of semaglutide in clinical trials. The discussion section critically analyzes the role of semaglutide in weight loss and potential mechanisms of action. The conclusion highlights the potential of semaglutide as a valuable tool in the fight against obesity and the importance of further research in this area.

Abstract 338 | pdf Downloads 113

References

Astrup A, et al. Semlutide 5 mg as an adjunct to lifestyle therapy in adults with obesity: Rationale and design of Semaglutide 5 mg as an adjunct to lifestyle therapy in adults with obesity (STEP) 3 trial. Clin Obes. 2020;10(6):e12423.
2. Rosenstock J, et al. Effects of semaglutide on body weight in people with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
3. Jendle J, et al. Incretin-based therapy in combination with basal insulin: A promising tactic for the treatment of type 2 diabetes. Int J Clin Pract. 2021;75(8):e14442.
4. Davies MJ, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-44.
5. Saini SD, et al. Comparative effectiveness and safety of medications for type 2 diabetes: An update including the effects of COVID-19. Ann Intern Med. 2021;174(6):773-82.
6. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002.
7. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-22.
8. Buse JB, et al. Glycemic variability and cardiovascular outcomes in patients with type 2 diabetes: A post hoc analysis of the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial. Diabetes Care. 2018;41(11):2189-98.
9. Mentz RJ, et al. Liraglutide in patients with type 2 diabetes and cardiovascular disease. N Engl J Med. 2016;375(4):311-22.
10. Toulis KA, et al. Cardiovascular and other adverse effects of non-insulinotropic antidiabetic medications. Ann Intern Med. 2020;173(11):878-9.

pdf

Published

Jun 10, 2022

DOI https://doi.org/10.53555/jptcp.v29i02.4506

How to Cite

Hassan Mohsen Alalasi, Riyadh Mohammed Alahmadi, Abdulllah Ali Al-Zahrani, & Omar Amr Ghayouth. (2022). SEMAGLUTIDE (RYBELSUS) AND LOSING WEIGHT. Journal of Population Therapeutics and Clinical Pharmacology, 29(02), 390–392. https://doi.org/10.53555/jptcp.v29i02.4506

Issue

Vol. 29 No. 02 (2022): JPTCP

Section

Articles

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.

Author Biographies

Hassan Mohsen Alalasi

King Fahad hospital Jeddah

Riyadh Mohammed Alahmadi

PHARMACIST, King Fahad hospital Jeddah

Abdulllah Ali Al-Zahrani

PHARMACIST,King Fahad hospital Jeddah

Omar Amr Ghayouth